Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table

Executive Summary

Generic user fees could be segmented further by addition of new group.

Advertisement

Related Content

Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’
Generic User Fees: FDA Goes On Backlog Offensive
ANDA Approval Improvements Reveal Just How Big The Backlog Is
ANDA Renaissance: FDA Aims To Reduce Refuse-To-Receive Actions
FDA Generic Office Director Uhl Returns From Medical Leave
Biosimilar User Fee Negotiations Won't Start Until 2016
GDUFA Stakeholder Deadline May Come After Negotiations Conclude
GDUFA Stakeholder Deadline Extended; Are Talks Delayed?
GDUFA Talks: FDA Reminds Industry The Program Is Generic-Only

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS056977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel